主页 > 医药科学 >
【文摘发布】西罗莫司扭转肝移植受体的肾功不
Author:Shenoy S, Hardinger KL, Crippin J, Desai N, Korenblat K, Lisker-Melman M, Lowell JA, Chapman W.
source: Transplantation. 2007 May 27;83(10):1389-92.
This pilot trial was designed to assess the safety and efficacy of SRL in liver transplant recipients with renal dysfunction. Forty patients with renal dysfunction (24-hr CrCl 40-80 mL/min) were randomized to be withdrawn from the calcineurin inhibitor (CNI) and receive sirolimus (SRL) or to continue CNI (control arm). Improvement in 24-hour CrCl was seen in the SRL arm at 3 months (75 mL/min SRL vs. 56 mL/min control, P=0.012), whereas at 12 months there was a trend toward improvement in the SRL arm (72 mL/min SRL vs. 58 mL/min control, P=0.09). Two patients, one in each arm, developed steroid-sensitive rejection. Side effects of SRL were limited and included hyperlipidemia requiring treatment (15%), pruritis (5%), and mouth sores (25%). In this trial, SRL-based immunosuppression was a safe alternative to CNI. Although early improvements were observed, withdrawing CNI and replacing it with SRL did not result in a statistically significant improvement in renal function at 12 months of follow-up. 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 Title:Sirolimus conversion in liver transplant recipients with renal dysfunction: a prospective, randomized, single-center trial.
题目：肾功不全肝移植受体的西罗莫司换用：一项前瞻性随机单中心试验
Author:Shenoy S, Hardinger KL, Crippin J, Desai N, Korenblat K, Lisker-Melman M, Lowell JA, Chapman W.
作者：Shenoy S, Hardinger KL, Crippin J, Desai N, Korenblat K, Lisker-Melman M, Lowell JA, Chapman W.
source: Transplantation. 2007 May 27;83(10):1389-92.
出处：《移植》杂志 2007年5月27日;83(10):1389-92.
This pilot trial was designed to assess the safety and efficacy of SRL in liver transplant recipients with renal dysfunction.
这项先导试验是设计用来评估西罗莫司用于肾功不全肝移植受体的安全性和有效性的。
Forty patients with renal dysfunction (24-hr CrCl 40-80 mL/min) were randomized to be withdrawn from the calcineurin inhibitor (CNI) and receive sirolimus (SRL) or to continue CNI (control arm).
40名肾功不全的患者（24小时内生肌酐清除率 40-80 mL/min）被随机选出停止服用钙调磷酸酶抑制剂(CNI)，转而服用西罗莫司(SRL)或继续服用CNI（对照组）。
Improvement in 24-hour CrCl was seen in the SRL arm at 3 months (75 mL/min SRL vs. 56 mL/min control, P=0.012), whereas at 12 months there was a trend toward improvement in the SRL arm (72 mL/min SRL vs. 58 mL/min control, P=0.09). Two patients, one in each arm, developed steroid-sensitive rejection.
在三个月里，SRL组患者24小时内生肌酐清除率得到了改善(75 mL/min SRL组 vs. 56 mL/min 对照组, P=0.012)，而在12个月里，SRL组患者仅出现了改善的趋势(72 mL/min SRL组 vs. 58 mL/min对照组, P=0.09).有两名患者（每组里有1名）出现了类固醇敏感的排斥反应。
Side effects of SRL were limited and included hyperlipidemia requiring treatment (15%), pruritis (5%), and mouth sores (25%). In this trial, SRL-based immunosuppression was a safe alternative to CNI.
通过一些措施对西罗莫司的副作用进行了限定，包括对高脂血症 (15%)，搔痒症(5%)和口腔溃疡(25%)进行治疗。在本试验中，以SRL为基础的免疫抑制疗法是以CNI为基础的免疫抑制疗法的一种安全替代。
Although early improvements were observed, withdrawing CNI and replacing it with SRL did not result in a statistically significant improvement in renal function at 12 months of follow-up.
虽然观察到了早期的改善，但在12个月的随访中，停用CNI而替换为SRL未引起肾脏功能在统计学上的显著改善。
编译：
字数：378字
肾功不全肝移植受体的西罗莫司换用：一项前瞻性随机单中心试验
《移植》杂志 2007年5月27日;83(10):1389-92. 作者：Shenoy S等
这项先导试验是设计用来评估西罗莫司用于肾功不全肝移植受体的安全性和有效性的。
40名肾功不全的患者（24小时内生肌酐清除率 40-80 mL/min）被随机选出停止服用钙调磷酸酶抑制剂(CNI)，转而服用西罗莫司(SRL)或继续服用CNI（对照组）。 在三个月里，SRL组患者24小时内生肌酐清除率得到了改善(75 mL/min SRL组 vs. 56 mL/min 对照组, P=0.012)，而在12个月里，SRL组患者仅出现了改善的趋势(72 mL/min SRL组 vs. 58 mL/min对照组, P=0.09).有两名患者（每组里有1名）出现了类固醇敏感的排斥反应。通过一些措施对西罗莫司的副作用进行了限定，包括对高脂血症 (15%)，搔痒症(5%)和口腔溃疡(25%)进行治疗。在本试验中，以SRL为基础的免疫抑制疗法是以CNI为基础的免疫抑制疗法的一种安全替代。虽然观察到了早期的改善，但在12个月的随访中，停用CNI而替换为SRL未引起肾脏功能在统计学上的显著改善。 [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-05-23 17:11
医学,生命科学网